The news this morning is that Kenilworth cleared FDA (older February 2014 background on it, here; February 2013 backgrounder here), but now must litigate with Sanofi, under the relevant Hatch-Waxman (up to 30 month) stay period. Of course, Merck could win out -- in the federal patent case, and launch sooner -- we shall see. From the NASDAQ-filed press release then -- a bit:
. . . .The U.S. Food and Drug Administration has granted [Merck/Samsung Bioepis] tentative approval for LUSDUNA Nexvue or insulin glargine injection 100 units/mL, a follow-on biologic basal insulin in a pre-filled dosing device. LUSDUNA Nexvue is being developed by Merck with funding from Samsung Bioepis.
With the tentative approval, LUSDUNA Nexvue has met all required regulatory standards for follow-on biologics of clinical and nonclinical safety, efficacy and quality, but is subject to an automatic stay due to a lawsuit from Sanofi claiming patent infringement. . . .
To this moment, we haven't reported on that piece of patent litigation very closely (as it was immaterial to Merck, until it secured FDA approval) -- but now we obviously will cover it -- and do so, closely. I'll get up to speed, on it -- with the baby on my lap, in the Loop -- tonight. Smile.
To be clear, at least two other life science major players have one bio-sim in the cue -- so the field could get crowded (background on Dr. Gottlieb's new initiative at FDA, here), and prices could drop -- pretty quickly.
In fairness to the historical record, Dr. Gottlieb is mostly putting forward a slightly-tweaked version of an early ObamaCare era proposal -- one that sort of fell by the wayside, in 2014. The idea is sound, and would benefit US consumers immensely, so I don't care if a Trump appointee says it is "new" (when it is in truth a revision of a 2012-13 proposed FDA policy) -- it remains a good idea, even if I know it was originally conceptualized under Mr. Obama. Now you know. Onward, into the rain -- but smiling, just the same. . . . whoosh!
नमस्ते
